UNIVERSITE DE MONTPELLIER;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS);Axlr, Satt Du Languedoc Roussillon
发明人:
申请号:
EP18305453.5
公开号:
EP3553061A1
申请日:
2018.04.12
申请国别(地区):
EP
年份:
2019
代理人:
摘要:
The invention relates to a compound of formula (I):and its use as drug, in particular for use in prevention and/or treatment of disease-associated bone loss, preferably selected in the group consisting of bone metastases, multiple myeloma, osteoporosis, osteopenia due to bone metastases, osteogenesis imperfecta, periarticular erosions in rheumatoid arthritis, primary hyperparathyroidism, hypercalcemia of malignancy, Paget's disease of bone, periodontal disease, immobilization induced osteopenia, and glucocorticoid treatment.